The request references two recent settlements with the office of New York Attorney General Eric Schneiderman and Anthem and Cigna ending preauthorization for the treatment.
“The AMA believes that attorneys general can reach the same agreement with all payers, and we pledge our public support in making that happen,” James Madara, MD, CEO and executive vice president of the AMA, wrote on behalf of the association.
Dr. Madara said manual and time-consuming processes used in preauthorization policies interrupt care for patients with opioid use disorder. “There is no medical, policy or other reason[,] for payers to use prior authorization for MAT, and we hope that New York’s efforts will be the first of many similar ones across the nation,” he added.
More articles on opioids:
CDC issues report on string of fentanyl overdoses in Connecticut: 5 takeaways
3 ways repealing ACA could exacerbate the opioid epidemic
Maryland governor proposes opioid prescription restrictions
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
